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Abstract: 
 
Selenium (Se) at supranutritional levels can enhance the activity of glutathione S-transferase 
(GST), whose gene is a target of nuclear factor erythroid-2 related factor 2 (Nrf2). Recent studies 
indicated that the thioredoxin reductase 1 (TrxR1) gene could also be targeted by Nrf2. Thus, 
high-dose Se may stimulate TrxR1 provided it enhances GST activity. Indeed, one study found 
that Se at supranutritional levels transiently increased hepatic TrxR1 activity. However, another 
study reported that supranutritional Se had no such effect on hepatic TrxR1 activity. In view of 
this discrepancy, the present research investigated whether high-dose Se has any impact on 
hepatic TrxR1. Moreover, we investigated whether Se preferentially activates GST over TrxR1. 
We observed that when sodium selenite (SS) caused liver injury, both hepatic TrxR1 activity and 
hepatic GST activity increased. Further experiments indicated that SS increased hepatic GST 
activity at either toxic or high but non-toxic dose levels; however, increase in hepatic TrxR1 
activity occurred only at toxic levels, suggesting that enhanced TrxR1 activity correlates with 
liver injury. To corroborate this, we showed that hepatotoxic agents, thioacetamide or carbon 
tetrachloride, caused marked increases in hepatic TrxR1 activity. In conclusion, high-dose SS 
indeed can enhance hepatic TrxR1 activity, but only on the condition that it causes liver injury. 
High-dose SS affects hepatic GST more readily than hepatic TrxR1. Thus, the cancer-preventive 
mechanism of Se at non-toxic supranutritional levels relies more on its modulation of GST rather 
than TrxR1, at least in liver tissue. 
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Article: 
 
1. Introduction 
 
Mammalian thioredoxin reductase (TrxR), a ubiquitous enzyme present in all living cells, is an 
NADPH-dependent homodimer oxidoreductase with one FAD and one selenocysteine per 
subunit (Nordberg and Arnér, 2001). The major substrate of TrxR is oxidized thioredoxin (Trx). 
Moreover, TrxR can directly reduce many endogenous and exogenous compounds such as 
selenium (Se) compounds, dehydroascorbic acid, lipid hydroperoxides and H2O2 (Arnér and 
Holmgren, 2000). There are three forms of mammalian TrxR isoenzymes: cytoplasmic TrxR 
(TrxR1), mitochondrial TrxR (TrxR2), and testis-specific TrxR with additional glutathione 
(GSH) reductase activity (TGR), all being selenoenzymes that share the same principal domain 
structure (Nordberg and Arnér, 2001). The Trx/TrxR system plays an important role in the redox 
regulation of multiple intracellular processes, including Se metabolism, DNA synthesis, 
transcriptional regulation, cell growth, and resistance to cytotoxic agents that induce oxidative 
stress and apoptosis (Kumar et al., 1992, Nordberg and Arnér, 2001). 
 
There are two different regulation pathways for TrxR1. First, as a selenoenzyme, TrxR1 activity 
in Se-deficient subjects increases in response to nutritional Se supplementation (Hadley and 
Sunde, 2001, Reeves et al., 2005). Secondly, the TrxR1 gene contains an antioxidant response 
element (ARE) in the promoter region that can be targeted by nuclear factor erythroid-2 related 
factor 2 (Nrf2). Thus, TrxR1 can be induced by certain oxidative stressors or electrophiles which 
drive Nrf2 into nucleus (Chen et al., 2005, Conterato et al., 2007, Hintze et al., 2003, Sakurai et 
al., 2005, Zhang et al., 2003). Like that of TrxR1, the promoter region of another selenoenzyme, 
gastrointestinal glutathione peroxidase (GI-GPx), also contains an ARE. Consequently, the GI-
GPx gene can be activated by electrophiles (Banning et al., 2005). 
 
Modulation of carcinogen metabolism by phase 2 enzymes, such as glutathione S-transferase 
(GST), is one of the most effective strategies for protecting animals against the neoplastic effects 
of carcinogens (Hayes et al., 2005, Talalay, 2000). The gene of GST is a well-established target 
of Nrf2 (Ramos-Gomez et al., 2001). There is a large body of evidence indicating that Se at 
supranutritional level can increase detoxifying activity of GST (Ip and Lisk, 1997, Sohn et al., 
1999, Wang et al., 2007, Xiao and Parkin, 2006), thus GST induction by Se is a potential 
mechanism of its cancer-preventive action. 
 
Since expression of both GST and TrxR1 is regulated by Nrf2, it is plausible that Se may 
stimulate TrxR1 provided it increases GST activity. However, reports about the impact of Se at 
supranutritional levels on TrxR1 are inconsistent. One study found supranutritional Se transiently 
increased hepatic TrxR1 activity (Berggren et al., 1999), whereas another reported it had no 
effect on hepatic TrxR1 activity (Ganther and Ip, 2001). In view of this discrepancy, one purpose 
of the present study was to investigate whether high-dose Se affects hepatic TrxR1. The second 
purpose was to investigate whether Se preferentially activates GST over TrxR1. 
 
2. Materials and methods 
 
2.1. Materials 
 
Nicotinamide-adenine dinucleotide phosphate (NADPH), hydroxyethyl piperazine 
ethanesulfonic acid (HEPES), insulin, guanidinium hydrochloride, Trx (E. coli), and SS were 
obtained from Sigma (St. Louis, MO, USA). Other reagents used were the highest grade 
available. Elemental Se at nanosize (Nano-Se, with an average size at 36 nm) was prepared 
according to the method previously reported by us (Zhang et al., 2001). 
 
2.2. Animals 
 
Male Kunming mice (weighing 22–24 g), male C57BL/6 mice (weighing 22–24 g), and their diet 
were all purchased from Shanghai Laboratory Animal Center (SLAC). Se content in the diet 
used in SLAC and the present study was 0.3 ppm, indicating the mice were Se-sufficient 
according to the study carried out by Hadley and Sunde (2001) or by Reeves et al. (2005). Male 
Sprague–Dawley rats (weighing 180–220 g) were purchased from the Animal Center, Anhui 
Medical University, Hefei, PR China. Animals were housed in plastic cages with controlled 
temperature (22 ± 1 °C) and humidity (50 ± 10%) and 12 h light/dark cycle. Animals were 
allowed ad libitum access to diet and water. 
 
2.3. Animal treatments 
 
Kunming mice were randomly divided into two groups with eight mice per group. Group I was 
intraperitoneally (i.p.) injected with saline as control and group II was i.p. injected with SS at 
2 mg Se/kg for 14 days. All mice were sacrificed 24 h after the last Se administration. 
 
C57BL/6 mice were randomly divided into five groups with eight mice per group. Saline (as 
control), SS and Nano-Se at 2 and 4 mg Se/kg were administered by gavage once daily for 28 
days. All mice were sacrificed 24 h later after the last Se administration. 
 
Sprague–Dawley rats were randomly divided into two groups with eight rats per group. Group I 
was i.p. injected with saline as control and group II was i.p. injected with thioacetamide (TAA) 
dissolved in saline at 200 mg/kg, twice weekly. All rats were sacrificed after 6 weeks of 
treatment. 
 
Sprague–Dawley rats were randomly divided into two groups with eight rats per group. Group I 
was i.p. injected with corn oil as control and group II was i.p. injected with carbon tetrachloride 
(CCl4) dissolved in corn oil (CCl4:corn oil = 1:4) at 5 ml/kg twice weekly. All rats were 
sacrificed after 6 weeks of treatments. 
 
Peripheral blood was collected and centrifuged at 3000 × g for 10 min to isolate serum. Livers 
were excised immediately and rinsed in ice-cold saline. The samples were stored at −30 °C 
before assay. 
 
All protocols involved in animal experiments complied with the guidelines of University of 
Science and Technology of China for the care and use of laboratory animals. 
 
2.4. Biomarkers 
 
The activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in serum 
were estimated by spectrophotometry using commercially available kits. Livers were 
homogenized with ice-cold saline and centrifuged at 15,000 × g at 4 °C for 15 min. The resulting 
supernatants were used for biochemical assessments. Protein level was determined by the 
Bradford dye-binding assay with bovine serum albumin as standard. Superoxide dismutase 
(SOD) was assayed using the system of xanthine–xanthine oxidase and nitroblue tetrazolium 
(NBT). One unit of SOD is defined as the amount of protein that inhibits the rate of NBT 
reduction by 50%. Data are expressed as U/mg of tissue protein (Sun et al., 1988). Glutathione 
peroxidase (GPx) activity was assayed by the method of Rotruck et al. (1973). The activity of 
GPx is expressed as units/mg protein; a unit is defined as 1 μmol of glutathione oxidized/min. 
GST activity was chemically determined by using CDNB. One unit of GST activity is calculated 
in terms of nmol CDNB changed/min/mg of tissue protein (Habig et al., 1974). 
 
TrxR1 activity was measured based on the method of Holmgren and Bjornstedt (1995) with 
some modifications. A stock mixture contained HEPES buffer (0.25 M), NADPH (2.5 mM), 
EDTA (10 mM), and insulin (1 mM), with the final pH 7.6. In a 96-well plate, 7 μl stock 
mixture, 3 μl Trx (0.17 mM), 40 μl HEPES (50 mM, pH 7.6), and 10 μl sample (with 20–30 μg 
protein) were added into a well. The enzymatic reaction was maintained at 37 °C for 20 min, and 
then was ceased by adding 240 μl termination solution (0.5 mM DTNB/6 M guanidine 
hydrochloride in 0.2 M Tris–HCl, pH 8.0). For each sample there was a parallel non-enzymatic 
reaction in which Trx was substituted by saline, but all other components were exactly same as 
the enzymatic reaction. The 96-well plates were read at 412 nm. The A412 increase was calculated 
by subtracting the absorbance of the non-enzymatic reaction from the absorbance of the 
enzymatic reaction. A background control, which was the subtraction of absorbance with and 
without Trx in the absence of sample, was further subtracted from the A412 increase. TrxR1 
activity unit was defined as A412 change × 1000/min (Ganther and Ip, 2001) and was expressed as 
U/mg protein. 
 
2.5. Histopathological observations 
 
Immediately after the sacrifice of the animals, livers were excised and rinsed with ice-cold 
saline. Then they were fixed in 10% neutral-buffered formalin solution, and embedded into 
molten paraffin wax. Tissue sections of 5 μm thickness were stained with hematoxylin and eosin 
(H&E) and observed under a light microscope by an experienced pathologist who was blind to 
the treatments. 
 
2.6. Statistical analysis 
 
Data are presented as the mean ± S.D. The difference between groups was examined by double 
sample analysis of variance followed by Student's t-test (two-tailed tests) or one-way ANOVA 
with post hoc Tukey test when multiple groups were compared. A p-value of less than 0.05 was 
considered statistically significant. 
 
3. Results and discussion 
 
3.1. SS induces liver injury and enhances hepatic TrxR1 and GST activities 
 
Mice were i.p. injected with SS at 2 mg Se/kg for 14 days. After the first 4 days of injections, SS 
significantly suppressed growth of the mice (Fig. 1A), thus indicating Se intoxication had 
occurred because growth suppression is recognized as part of the profile of Se intoxication in 
mice or rats (Thorlacius-Ussing, 1990, Gronbaek et al., 1995). Liver tissue is a major target of Se 
intoxication (Diskin et al., 1979), so we examined liver injury after 14 days of injections. SS 
significantly increased serum ALT and AST activities (Fig. 1B) and caused moderate hydropic 
degeneration in most hepatocytes (Fig. 1C). 
 
 
Fig. 1. SS induces liver injury and enhances hepatic TrxR1 and GST activities. Kunming mice 
were i.p. injected with SS at 2 mg Se/kg for 14 days: (A) growth curve; (B) serum ALT and AST 
activities; (C) photomicrograph of liver tissue in SS-treated mice. Original magnification: H&E 
staining 100×. Arrows indicate moderate hydropic degeneration. (D) Redox parameters in liver. 
The average GPx, SOD, TrxR1 and GST activities in the control were 2138, 26.2, 105.8 and 
4123 U/mg protein, respectively. Data are presented as mean ± S.D. (n = 8). 
 
Excess SS possesses pro-oxidant activity through its ability to catalyze the oxidation of 
sulfhydryls, by which it can inactivate some enzymes (Spallholz and Hoffman, 2002) such as 
delta-aminolevulinate dehydratase (Barbosa et al., 1998). It can also promote the formation of 
reactive oxygen species (ROS) (Spallholz, 1994). We found SS decreased SOD and GPx 
activities (Fig. 1D), two enzymes that are paramount for defense against ROS. The production of 
ROS due to excess SS (Spallholz, 1994) along with compromised free radical scavenging 
capacity (Fig. 1D) together indicates a state of oxidative stress. Oxidative stress can induce 
TrxR1 (Chen et al., 2005, Conterato et al., 2007, Sakurai et al., 2005). Not surprisingly, we found 
SS significantly enhanced hepatic TrxR1 activity by 80% (Fig. 1D). TrxR1 plays an important 
role in defending against oxidative stress (Nordberg and Arnér, 2001). TrxR1 also reduces SS 
into elemental Se with lower toxicity (Kumar et al., 1992). Cells over-expressing TrxR1 are 
more resistant to SS-induced cytotoxicity (Madeja et al., 2005). Thus, enhancement of TrxR1 
activity may serve as an important adaptive response to cope with excess SS. 
 
In our experiments, increased hepatic TrxR1 activity cannot simply be ascribed to nutritional Se 
supplementation because (1) diet with 0.1–0.3 ppm Se is sufficient to saturate selenoenzymes in 
animals (Hadley and Sunde, 2001, Reeves et al., 2005), whereas dietary Se content in the present 
study was 0.3 ppm and (2) TrxR1 can be saturated more readily than GPx in response to Se 
supplementation (Reeves et al., 2005) since TrxR1 ranks higher than GPx in view of the 
hierarchy of selenoenzymes (Berry, 2005). Given that enhanced TrxR1 activity was a result of Se 
supplementation, GPx activity should also increase. In contrast, we observed GPx activity 
significantly decreased (Fig. 1D). 
 
In addition to TrxR1, we also found SS significantly increased hepatic GST activity (Fig. 1D). 
As indicated earlier, GST activity can be enhanced by Se at high but non-toxic dose levels (Ip 
and Lisk, 1997, Sohn et al., 1999, Wang et al., 2007, Xiao and Parkin, 2006). As to TrxR1, the 
reported results are inconsistent (Berggren et al., 1999, Ganther and Ip, 2001). Thus we next 
investigated the impact of Se on TrxR1 at high but non-toxic dose levels. 
 
3.2. Enhancement of hepatic TrxR1 activity depends upon liver injury 
 
Mice were orally administered with SS at 2 and 4 mg Se/kg for 28 days. SS at 4 mg Se/kg caused 
significant growth suppression (Fig. 2A) and liver injury indicated by either ALT activity (Fig. 
2B) or histopathological alterations, predominantly in the form of inflammatory cell infiltration 
(Fig. 2C). SS at 2 mg Se/kg neither caused growth suppression (Fig. 2A) nor induced liver injury 
as evidenced by serum ALT activity (Fig. 2B) and histopathological observation (not shown). 
 
SS at 4 mg Se/kg significantly increased hepatic TrxR1 activity, by 190%, whereas at 2 mg 
Se/kg did not affect its activity (Fig. 2D). The enhanced TrxR1 activity cannot be ascribed to 
nutritional Se supplementation because 2 mg Se/kg by daily oral gavage (a dose at least 20-fold 
higher than nutritional supplementation) for 28 days did not increase TrxR1 activity as compared 
with the control, demonstrating TrxR1 activity in the control had already been saturated. 
 
Consistent with the notion that GST activity can be enhanced by Se at high but non-toxic dose 
levels, herein SS at 2 mg Se/kg, which had no toxicity, significantly increased GST activity (Fig. 
2E). These data demonstrate that hepatic GST can be induced prior to liver injury, whereas 
hepatic TrxR1 induction correlates with liver toxicity. Based on this notion, we inferred that at 
an equivalent high dose, a Se compound with less liver toxicity would not affect hepatic TrxR1. 
To test this hypothesis, Nano-Se was used, because our previous studies indicate it possesses 
noticeably lower toxicity as compared with SS, selenomethione and methylselenocysteine. 
However, the bioavailability of Nano-Se at nutritional levels is similar to these other Se 
compounds (Zhang et al., 2001, Zhang et al., 2005, Zhang et al., 2007, Wang et al., 2007). 
Moreover, the impact of Nano-Se at supranutritional levels on GST activity is equivalent to 
methylselenocysteine (Zhang et al., 2007), and appears to be even higher than SS and 
selenomethione (Zhang et al., 2005, Wang et al., 2007). In parallel with SS treatment, mice were 
orally administered Nano-Se at either 2 or 4 mg Se/kg for 28 days. In contrast to SS, Nano-Se at 
4 mg Se/kg neither suppressed growth (Fig. 2A) nor caused liver injury (Fig. 2B) to the animals. 
As predicted, hepatic TrxR1 activity did not change (Fig. 2D). It must be pointed out that the 
lack of toxicity or increment in TrxR1 activity cannot be ascribed to the possibility that Nano-Se 
is inert in this situation, because it increased GST activity more efficiently than SS at both 2 and 
4 mg Se/kg doses (Fig. 2E). 
 
 
Fig. 2. Hepatic TrxR1 and GST activities at toxic and non-toxic dose levels of Se. C57BL/6 mice 
were orally administered with SS and Nano-Se at 2 and 4 mg Se/kg once daily for 28 days: (A) 
growth curve; (B) serum ALT activity; (C) photomicrograph of liver tissue in SS-treated mice. 
Original magnification: H&E staining 100×. Arrows indicate inflammatory cell infiltration. (D) 
Hepatic TrxR1 activity and (E) hepatic GST activity. Data are presented as mean ± S.D. (n = 8). 
 
It is worth noting that a recent study reported that high but non-toxic doses of SS increased both 
TrxR1 and GST activities in liver (El-Sayed et al., 2006), whereas, under similar conditions, the 
present study observed only the latter. This discrepancy may be due to the assay method used for 
TrxR activity. We used the standard TrxR assay method with thioredoxin as substrate and 
oxidized insulin as the final electron acceptor (Holmgren and Bjornstedt, 1995). In El-Sayed's 
report, TrxR activity was estimated using the aurothioglucose-sensitive rate of reduction of 5,5-
dithio-bis-(2-nitrobenzoic acid) by NADPH. Furthermore, their data related to TrxR activity and 
mRNA were somewhat paradoxical. First, they used oltipraz, a chemopreventive agent, as 
reference. Oltipraz led to a fivefold induction of TrxR mRNA, but with no corresponding 
increase in TrxR activity. On the contrary, in their hands, SS did not induce TrxR mRNA, but 
did produce an apparent increase in TrxR activity. Secondly, the control value of serum ALT 
activity in the mice they used was 44.43 ± 4.51 (mean ± S.E.M.); after oltipraz treatment, this 
increased to 61.53 ± 23.33. Although not significant statistically, the increase and the large 
S.E.M. of ALT in oltipraz-treated mice suggests that oltipraz had caused liver injury in a portion 
of the mice. Accordingly, TrxR mRNA markedly increased by fivefold due to liver injury. 
However, their observation that TrxR activity did not thereby increase seems unreasonable. 
Whether this was because of the assay method for TrxR activity is unclear. On the other hand, 
El-Sayed et al. claimed that SS at the prescribed doses and times did not cause liver toxicity, 
based only on ALT evaluation. The basal ALT activity in the mice they used was 44.43, which 
could be considered as a high basal value; although SS did not appear to significantly increase 
ALT activity beyond that level, one cannot totally exclude the possibility of liver injury, since 
according to our data, in mice with low basal ALT activity, SS only modestly but significantly 
increased ALT (from 20.8 to 34.7, Fig. 1B; from 23.8 to 33.8, Fig. 2B). However, a histological 
examination (which was not performed by El-Sayed et al.) revealed that the underlying liver 
injury was severe (Fig. 1, Fig. 2). 
 
To further corroborate the hypothesis that the increase in hepatic TrxR1 correlates with liver 
toxicity, we next used the potent hepatotoxic agents TAA and CCl4 to generate liver injury in 
rats, to see if this was sufficient to produce a change in hepatic TrxR1 activity. 
 
3.3. Both TAA and CCl4 enhance hepatic TrxR1 activity 
 
Six weeks of TAA or CCl4 treatment caused severe liver injury, indicated by serum ALT and 
AST activities (Fig. 3, Fig. 4), as well as histopathological alterations, predominantly in the 
forms of coarse fibrous septa with inflammatory cell infiltration (TAA, Fig. 3B) and coarse 
diffuse steatosis (CCl4, Fig. 4B). In the mean time, both hepatotoxic agents significantly 
increased hepatic TrxR1 activity, by 86–100% (Fig. 3, Fig. 4). 
 
 
Fig. 3. TAA enhances hepatic TrxR1 activity. TAA was i.p. injected twice weekly for 6 weeks: 
(A) serum ALT and AST activities; (B) photomicrograph of liver tissue in TAA-treated rats. 
Original magnification: H&E staining 100×. Arrows indicate coarse fibrous septa with 
inflammatory cell infiltration. (C) Hepatic TrxR1 activity. Data are presented as mean ± S.D. 
(n = 8). 
 
 
Fig. 4. CCl4 enhances hepatic TrxR1 activity. CCl4 was i.p. injected twice weekly for 6 weeks: 
(A) serum ALT and AST activities; (B) photomicrograph of liver tissue in CCl4-treated rats. 
Original magnification: H&E staining 100×. Ellipses indicate coarse diffuse steatosis. (C) 
Hepatic TrxR1 activity. Data are presented as mean ± S.D. (n = 8). 
 
In conclusion, although the genes of both GST and TrxR1 are targets for Nrf2, SS induces 
hepatic GST more readily than hepatic TrxR1. High-dose SS indeed can increase hepatic TrxR1 
activity, but on the condition that it causes liver injury. The cancer-preventive mechanism of Se 
at supranutritional level thus is more likely to rely on its modulation of GST rather than TrxR1, 
at least in liver tissue. 
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